Comparative Effectiveness of Novel Oral Anticoagulants in Obese Patients with Atrial Fibrillation
DOI:
https://doi.org/10.63682/jns.v13i1.9360Keywords:
Obesity, Atrial Fibrillation, Novel Oral Anticoagulants, Apixaban, Stroke Prevention, Major BleedingAbstract
Background: Atrial fibrillation (AF) is a leading cause of stroke worldwide, and obesity is a recognized risk factor that may influence the pharmacokinetics of anticoagulants. The optimal choice of novel oral anticoagulant (NOAC) for obese AF patients remains uncertain, with limited comparative data available.
Methodology: This prospective observational study was conducted from March 2023 to March 2024, enrolling 72 obese patients (BMI ≥ 30 kg/m²) with non-valvular AF. Participants were divided into four groups according to the NOAC prescribed: Apixaban, Rivaroxaban, Dabigatran, or Edoxaban. Baseline demographic data, comorbidities, CHA₂DS₂-VASc and HAS-BLED scores were recorded. Patients were followed for 12 months ‘to evaluate effectiveness outcomes (stroke/systemic embolism, AF-related hospitalization, all-cause mortality) and safety outcomes (major bleeding, gastrointestinal bleeding, intracranial hemorrhage, discontinuation due to adverse events)’.
Results: Apixaban users had ‘the lowest rate of stroke/systemic embolism (5.6%) and major bleeding’ (5.6%) compared with Rivaroxaban, Dabigatran, and Edoxaban groups. The difference in major bleeding was statistically significant (p = 0.03), whereas other outcomes showed favorable but non-significant trends. Hospitalization and mortality rates were comparable across groups (p > 0.05).
Conclusion: This study suggests that Apixaban provides a safer profile with significantly lower major bleeding and a trend toward fewer thromboembolic events in obese AF patients. Apixaban may be preferred for anticoagulation in this population, although larger multicenter studies are warranted to validate these findings
Downloads
References
Briasoulis, A., et al., Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation. 2021. 35(2): p. 261-272.
Alexandros, B., et al., Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. 2021. 35(2): p. 261-272.
Peterson, E.D., et al., Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. 2019. 212: p. 113-119.
Boivin-Proulx, L.-A., et al., Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation. 2022. 4(4): p. 395-405.
Russo, V., et al. Clinical performance of nonvitamin K antagonist oral anticoagulants in real-world obese patients with atrial fibrillation. in Seminars in Thrombosis and Hemostasis. 2020. Thieme Medical Publishers, Inc.
Kido, K. and S.J.A.o.P. Ngorsuraches, Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. 2019. 53(2): p. 165-170.
Thangjui, S., et al., Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. 2022. 8(4): p. 325-335.
Zhou, Y., J. Ma, and W.J.A.J.o.C.D. Zhu, Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis. 2020. 20(1): p. 51-60.
Patti, G., et al., Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. 2020. 318: p. 67-73.
Deitelzweig, S., et al., Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. 2020. 9(6): p. 1633.
Kido, K., et al., Meta-analysis comparing direct oral anticoagulants versus warfarin in morbidly obese patients with atrial fibrillation. 2020. 126: p. 23-28.
Malik, A.H., et al., Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis. 2020. 22(3): p. 361-367.
Elshafei, M.N., et al., Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. 2021. 51(2): p. 388-396.
Mhanna, M., et al., Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. 2021. 28(5): p. e531-e539.
Grymonprez, M., et al., Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review and meta-analysis. 2022. 36(4): p. 749-761.
Shaikh, F., et al., Effectiveness of direct oral anticoagulants in obese adults with atrial fibrillation: a systematic review of systematic reviews and meta-analysis. 2021. 8: p. 732828.
Karakasis, P., et al., Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis. 2024. 13(13): p. 3784.
Camm, A.J., et al., Comparative effectiveness of oral anticoagulants in everyday practice. 2021. 107(12): p. 962-970.
Kaplan, R.M., et al., Efficacy and safety of direct oral anticoagulants for atrial fibrillation across body mass index categories. 2020. 9(24): p. e017383.
Yao, X., et al., Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation. 2020. 13(10): p. e006515.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
